Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung
Recruitment status was Recruiting
The aim of this study to evaluate clinical efficacy of tiotropium in patients with airflow obstruction due to Tuberculosis (TB) destroyed lung.
Lung Disease, Obstructive
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Clinical Efficacy of Tiotripium in Patients With Airflow Obstruction Due to TB Destroyed Lung|
- St-George respiratory questionnaire(SGRQ) [ Time Frame: 6 months after initiation of tiotropium once-daily inhalation ] [ Designated as safety issue: No ]
- lung function [ Time Frame: 6mo after initiation of tiotropium once-daily inhalation ] [ Designated as safety issue: Yes ]
- cough VAS [ Time Frame: 6mo after initiation of tiotropium once-daily inhalation ] [ Designated as safety issue: No ]
- adverse reaction of tiotropium [ Time Frame: 6 months after initiation of tiotropium once-daily inhalation ] [ Designated as safety issue: Yes ]
|Study Start Date:||June 2011|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
|Tiotropium in TB destroyed lung|
Tuberculosis can cause lung parenchymal destruction, volume loss, secondary bronchiectasis. Patients with TB destroyed lung complain chronic respiratory symptoms, such as chronic cough, sputum, dyspnea, exercise intolerance, and acute exacerbations. Some of them have chronic airflow obstructions on pulmonary function tests, similar to those of smokers.
Previous large randomized controlled trials, targeting patients with smoking related moderate to severe COPD,demonstrated that tiotropium improved quality of life and respiratory symptom with tolerable long-term safety. The investigators want to evaluate whether tiotropium can improve chronic respiratory symptom,an lung function in patients with COPD due to TB destroyed lung.
|Korea, Republic of|
|Seoul National University Bundang Hospital||Recruiting|
|Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707|
|Contact: Sei Won Lee, M.D. 82-31-787-7053 email@example.com|
|Principal Investigator:||Sei Won Lee, M.D.||Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical research center, Seoul National University Bundang Hospital|